Esperion Therapeutis.Inc. buy blaugold
Summary
This prediction ended on 15.05.21 with a price of €17.60. The BUY prediction by blaugold finished with a performance of 19.24%. blaugold has a follow-up prediction for Esperion Therapeutis.Inc. where he still thinks Esperion Therapeutis.Inc. is a Buy. blaugold has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | -11.554% | -11.554% | 20.382% | -86.376% |
iShares Core DAX® | 1.665% | 1.692% | 18.093% | 15.353% |
iShares Nasdaq 100 | -0.475% | 1.483% | 27.860% | 36.314% |
iShares Nikkei 225® | 2.620% | 4.475% | 17.651% | 10.750% |
iShares S&P 500 | -0.091% | 1.099% | 24.873% | 36.740% |
Comments by blaugold for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Current prediction by blaugold for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
17.08.24
17.08.25
22:26
Stopped prediction by blaugold for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
24.07.23
24.07.24
05.08.23
Esperion Therapeutis.Inc.
15.05.23
15.05.24
29.05.23
Esperion Therapeutis.Inc.
16.04.23
16.04.24
29.04.23
Esperion Therapeutis.Inc.
03.08.21
03.08.22
12.08.21
Esperion Therapeutis.Inc.
11.08.20
26.08.20
26.08.20